RET, a gene causatively mutated in Hirschsprung disease and cancer, has recently been implicated in breast cancer estrogen (E2) independence and tamoxifen resistance. RET displays both E2 and retinoic acid (RA)-dependent transcriptional modulation in E2-responsive breast cancers. However, the regulatory elements through which the steroid hormone transcriptional regulation of RET is mediated are poorly defined. Recent genome-wide chromatin immunoprecipitation-based studies have identified 10 putative E2 receptor-alpha (ESR1) and RA receptor alpha-binding sites at the RET locus, of which we demonstrate only two (RET 249.8 and RET 132.8) display significant E2 regulatory response when assayed independently in MCF-7 breast cancer cells. We demonstrate that endogenous RET expression and RET 249.8 regulatory activity are cooperatively regulated by E2 and RA in breast cancer cells. We identify key sequences that are required for RET 249.8 and RET 132.8 E2 responsiveness, including motifs known to be bound by ESR1, FOXA1 and TFAP2C. We also report that both RET 249.8 regulatory activity and endogenous RET expression are completely dependent on ESR1 for their (E2)-induction and that ESR1 is sufficient to mediate the E2-induced enhancer activity of RET 249.8 and RET 132.8. Finally, using zebrafish transgenesis, we also demonstrate that RET 249.8 directs reporter expression in the central nervous system and peripheral nervous system consistent with the endogenous ret expression. Taken collectively, these data suggest that RET transcription in breast cancer cells is modulated by E2 via ESR1 acting on multiple elements collectively.
INTRODUCTION
The RET gene encodes a critical receptor tyrosine kinase required for the genesis and function of neurodendocrine, neuronal and renal populations. As such, its expression is tightly controlled throughout development and postnatal life. During vertebrate embryogenesis, RET is expressed in discrete subsets of neurons in the central and peripheral nervous systems and in the forming kidneys (1 -3) . RET gain-of-function mutations result in multiple endocrine neoplasia type 2 (4). In contrast, loss of function mutations in RET underlie Hirschsprung disease, a congenital defect marked by enteric aganglionosis (5) . RET enhancer mutations have also been implicated in Hirschsprung disease risk (6, 7) .
Additional evidence suggests a potentially important role for RET in breast cancer (8 -10) . While, similar to other tyrosine kinases, RET mutations are rarely identified in breast cancer (11) , RET over-expression with a corresponding increase in protein levels is detected in a subset of estrogen receptor-alpha (ESR1) positive invasive breast cancers (8, 12) . Further studies showed increased RET expression positively correlates with ESR1 expression in breast cancer (13, 14) . Additionally, RET-dependent Glial cell line-derived neurotrophic factor signaling in ESR1-positive breast cancer cell lines causes increased cell scattering and anchorage-independent proliferation (12, 13) . RET rearrangements were also detected in 8 out of 62 high-grade invasive ductal breast cancers (15) , and furthermore expression of the thyroid cancer-associated RET/PTC1 fusion protein led to mammary gland carcinoma in 18% of transgenic mice (16) . RET signaling has also been implicated in breast cancer estrogen (E2) independence and tamoxifen resistance, potentially through ESR1 phosphorylation causing ligand-independent transcriptional regulation (17, 18) . These data strongly suggest a role for RET and its modulation by E2 in breast cancer progression. Further, the ligand independent activation of ESR1 by the ESR1 target gene RET opens the possibility of an autoregulatory loop.
Consistent with the potential role of RET in breast cancer and the correlation of RET expression with ESR1 status, a growing body of data suggests that E2 and retinoic acid (RA) play significant roles in modulating RET transcription during development and disease (19 -24) . Both E2 and RA modulate transcription through their cognate nuclear receptors [ESR1 and RA receptor-alpha (RARA) (25, 26) ]. Both E2 and RA have been reported to regulate RET expression in the developing kidney (19, 21, 27) . RA has also been shown to regulate RET expression in neuroblastoma and interact with RET signaling in the enteric nervous system (22, 23, 28) . Upon RA exposure in the MCF-7 E2 responsive breast cancer cell line, RET is transcriptionally upregulated (29) . Similarly, RET is upregulated by E2 exposure in MCF-7 cells (20, 30) . Although ESR1-and RARA-binding sites often overlap and mediate antagonistic effects on gene regulation in MCF-7 cells, RET is one of a small minority of genes that is upregulated by both RA and E2 (29, 30) . Furthermore, recent chromatin immunoprecipitation (ChIP)-based studies identified ESR1-and RARA-binding sites genomewide in MCF-7 cells (20, (29) (30) (31) (32) (33) , including 10 ESR1-binding sites and two RARA-binding sites within and flanking RET. Although the declining cost of high throughput sequencing has allowed for a large increase in ChIP-Seq data, much follow up work remains to aid in the interpretation of whole genome data. Although regulatory element at the RET locus has been studied extensively (34) (35) (36) , to date no RET E2 response element has been identified. Additionally, no breast cancer RET locus RA response elements (RAREs) have been reported to date.
One recent study described chromatin interactions elicited by E2 stimulation in MCF-7 cells using chromatin interaction analysis by paired end tagging sequencing (ChIA-PET) (37) . Their results suggest that E2 signaling is frequently mediated through long-range chromatin interactions, including one interaction unit at the RET locus extending over 89 kb and involving five identified ESR1-binding sequences. Although commonly accepted models of enhancer -promoter interaction involve looping of intervening DNA to place an enhancer in proximity to its cognate promoter (38, 39) , we know little of the potential consequences of two or more enhancers acting in concert at a common promoter. Some data suggest a simple model of additive autonomy (40) , while other data suggest enhancers display cooperativity that is greater than additive (37, 41, 42) .
Despite the growing body of evidence indicating a role for RET in breast cancer, little is known about the sequences that mediate the transcriptional response of RET to steroid hormone super-family members, or how they mediate this effect. We report the characterization of two potent RET locus E2 responsive elements (EREs, RET 249.8 and RET +32.8) found by testing the 10 ESR1-binding sites identified by recent whole genome ChIP assays (20, 30, 31, 33) . RET 249.8 also contains a RARA-binding site (29) and similarly demonstrates RA responsiveness. We report that endogenous RET expression and RET 249.8 directed reporter expression are cooperatively regulated by E2 and RA. We identify several key motifs required for the E2 responsiveness of RET 249.8 and RET +32.8. Additionally, the collective regulatory activity of five interacting RET locus ESR1-binding sites can be explained by the activity of RET 249.8 and RET +32. 8 . Finally, we demonstrate the human RET 249.8 sequence directs RET appropriate neuronal regulatory control when assayed in transgenic zebrafish embryos.
RESULTS

Identification of E2 and RA responsive elements at RET
We set out to determine the E2 and RA responsiveness of sequences encompassing ChIP-identified ESR1-and RARAbinding sites at the RET locus. We defined the corresponding locus as the 300 kb interval encompassing RET and flanked by BMS1 and CSGALNACT2 (chr10:42653245-42948563; hg18). Taken collectively, recent genome-wide MCF-7 ChIPbased studies have identified 10 RET locus ESR1-binding sites [RET 294.4, RET 249.8, RET 238.1, RET 231.7, RET 215.8, RET 28.7, RET +4.8, RET +9.7, RET +28.1 and RET +32.8; Figure 1A ; Supplementary Material, Tables S1 and S2; (20, (30) (31) (32) (33) ], all named here according to their distance from the RET transcriptional start site, and two RET locus RARA-binding sites (RET 249.8 and RET 223). We cloned sequences encompassing these sites individually into a luciferase reporter vector and assayed their capacity to modulate reporter levels in response to E2 (17-b-estradiol) and RA (all-trans RA) in transfected MCF-7 cells (Fig. 1B  and C) . Of the 10 identified ESR1-binding sites, only RET 249.8 and RET +32.8 displayed significant E2 responsiveness, exhibiting 10-and 7-fold upregulation, respectively, versus the promoter-only construct in response to E2 treatment ( Fig. 1B; RET 249.8, P-value ,0.001; RET +32.8, P-value ,0.001). Consistent with these data, RET 249.8 and RET +32.8 also show E2 responsiveness when assayed in another ESR1-positive breast cancer cell line (T47D, Supplementary Material, Fig. S1A ). Similarly, of the two identified RARAbinding sites, only RET 249.8 displayed upregulation in response to RA in MCF-7 cells (Fig. 1C, 2 .7-fold, P value ,0.005). These data demonstrate that while RET +32.8 acts only as an ERE in these assays, RET 249.8 can behave as both an ERE and a RARE.
RET 249.8 exhibits greater than additive response to combined E2 and RA treatment Given the recent reports of crosstalk between the E2 and RA signaling pathways (29) Fig. S1B ).
Endogenous RET is cooperatively regulated by E2 and RA signaling
Given the synergistic activation of RET 249.8 by E2 and RA signaling, we then assayed the effects of the combined treatment of E2 and RA on endogenous RET gene expression in MCF-7 cells (Fig. 2B) . Consistent with previous reports (20, 29, 43) , RET was upregulated in MCF-7 cells following 24 h of E2 treatment ( Fig. 2B ; 7.4-fold RET upregulation versus hormone deprived condition, P-value ,0.0001) or 24 h of treatment with RA ( Fig. 3A; 1.6-fold versus hormone deprived condition, P-value ,0.001). Simultaneous treatment with E2 and RA upregulated of RET in a manner consistent with a cooperative model (multiplicative) ( Fig. 2B ; 18-fold in RA + E2 versus 7.4-fold in E2 treated and 1.6-fold in RA treated), but not synergistic upregulation (test for whether combined effect is greater than multiplicative has P-value .0.15). Although the magnitude of the combined response differs, both RET and the RET 249.8 construct display greater than additive responses to RA and E2 in combination. The difference observed in their magnitude of response may simply reflect the evaluation of RET 249.8 out of genomic context using a heterologous promoter.
Identification of key motifs for RET 249.8 E2 responsiveness
We then set out to identify sequences within RET 249.8 required for its E2 responsive regulatory activity. Intervals within the ERE RET 249.8 have been reported to bind ESR1 as well as the pioneer factor FOXA1 (30, 37, 44) . Additionally, RET 249.8 can be bound by TFAP2C, which regulates RET and many other parts of the E2 receptor signaling pathway. Using published transcription factor position weight matrices, we identified two FOXA1-like and two TFAP2C motifs overlapping previously published MCF-7 DNase hypersensitivity sites, a robust predictor of transcription factor binding [(45 -48) ; UW ENCODE Group; Fig. 3A ]. Furthermore, we also selected a 9 bp putative critical region (CR) and a 12 bp putative CR within RET 249.8 We then mutated the identified motifs to determine their effect on RET 249.8 regulatory activity. All RET 249.8 constructs (wild-type and mutants) were assayed for their effects on E2 response (Fig. 3B) . Mutation of either FOXA1-like motif (FOXA1 S1 and S2) resulted in the near loss of RET 249.8 reporter responsiveness to E2 ( Fig. 3B ; FOXA1 S1 and S2 P-value for reduction versus wild-type ,0.004). Further, mutation of the 9 bp CR and the 12 bp CR both resulted in significantly reduced but not abrogated E2 response ( Fig. 3B ; 12 bp CR P-value for reduction versus wild-type ,0.05; 9 bp CR P-value ,0.01), suggesting there may be redundancy in ESR1-binding sites. Mutagenesis of either TFAP2C site (TFAP2C S1 and TFAP2C S2) in the RET 249.8 luciferase vector led to highly reduced E2 response ( Fig. 3B ; TFAP2C S1 and TFAP2C S2 P-value for reduction versus wild-type ,0.001). These data suggest that the 9 bp CR, 12 bp CR, TFAP2C-like motifs and FOXA1-like motifs are critical components of RET 249.8 regulatory control in response to E2 (32) .
Identification of key motifs for RET 132.8 E2 responsiveness
Having identified sequences critical for independent RET 249.8 function, we similarly set out to test the necessity of sequences within RET +32.8 E2 responsiveness. RET +32.8 is bound by TFAP2C and ESR1, but not FOXA1 or RARA (26, 29, 37, 44, 49) . We identified an ESR1 motif in the ESR1-binding peak and a TFAP2C motif in the TFAP2C-binding peak within an MCF-7 DNase hypersensitivity site (TFAP2C S3) by integrating published motifs and the rVISTA2.0 tool [http://rvista.dcode.org/; Fig. 3C ; UW Encode Group; (47, 49, 50) ]. While the wild-type RET +32.8 showed E2 responsiveness, mutagenesis of the ESR1 motif or the TFAP2C S3 motif led to significant reduction in E2 response ( Fig. 3D ; ESR1 mutant P-value versus wild-type ,0.001, TFAP2C S3 mutant P-value versus wild-type ,0.001), indicating a critical role for those motifs in RET +32.8 function.
ESR1 is necessary for E2-mediated transcriptional modulation of RET and RET E2 response elements
Since RET is a primary target of E2 signaling and ESR1 binds RET 249.8 and RET +32.8, we tested whether ESR1 is necessary for E2-mediated modulation of endogenous RET expression and RET 249.8 and RET +32.8 regulatory activity in MCF-7 cells using siRNA-mediated knockdown ( Fig. 4A  and F ). Unlike treatment with control non-targeting siRNA, ESR1 siRNA treatment resulted in a complete abrogation of E2-induced RET upregulation ( Fig. 4A ; P-value 0.52). Similarly, treatment with ESR1 siRNA almost completely prevents RET 249.8 and RET +32.8 directed reporter E2 responsiveness (Fig. 4B) . Treatment with the selective E2 receptor modulator tamoxifen also reduced E2 responsiveness of RET 249.8 (Supplementary Material, Fig. S2 ), taken together with the effect of ESR1 siRNA suggests that ESR1 is critical and dependent on its ligand for eliciting the RET 249.8 E2 response. Additionally, consistent with its role as an ESR1 pioneer co-factor (44) that binds RET 249.8, FOXA1 siRNA knockdown reduced but did not completely eliminate endogenous RET E2 responsiveness (Fig. 4C, 1 .6-fold versus E2-deprived non-targeting siRNA). Similar to endogenous RET expression, FOXA1 knockdown reduced but did not abrogate RET 249.8 E2 responsiveness (Fig. 4D) . These data support the model that RET 249.8 and RET +32.8 act as ESR1-dependent EREs in a manner consistent with endogenous RET expression and raises the question of whether ESR1 is sufficient for this activity. E2-depleted (blue bars), RA exposed (green bars), E2 exposed (red bars), E2 and RA combined (purple bars) pDSMA RET 249.8 construct expression values were normalized against a promoter-only construct. All assays were conducted in triplicate (error bars, standard deviation). (B) Quantitative real-time polymerase chain reaction (PCR) measures effects of E2 deprivation (blue bars), E2 (red bars), RA exposed (green bars) or E2 and RA combined (purple bars) on endogenous MCF-7 RET expression, normalized to 18S rRNA. RET expression levels in E2-deprived cells were set as a level of 1-fold expression level.
* * P-value , 0.005; * * * P-value , 0.0005.
ESR1 is sufficient to induce RET 249.8 and RET 132.8 directed E2 responsiveness in ESR1-negative MDA-MB-231 cells
We tested the sufficiency of ESR1 to facilitate E2-induced RET 249.8 and RET +32.8 regulatory activity using the MDA-MB-231 (human ESR1-negative breast cancer) cell line ( Fig. 4E and H) (51) . E2 treatment did not induce increased luciferase activity in cells co-transfected with RET 249.8 or RET +32.8 luciferase vector and an empty expression vector (pCDNA3.1 empty) ( Fig. 4E ; RET 249.8 pCDNA 3.1 empty P-value .0.10; RET +32.8 pCDNA 3.1 empty P-value .0.25). In contrast, E2 treatment of cells co-transfected with the RET 249.8 luciferase vector and a plasmid constitutively expressing ESR1 (pCDNA3.1 ESR1; Fig. 4H ) induced luciferase activity at levels 20-fold higher than the promoter-only construct ( Fig. 4E ; P-value versus promoter ,0.001). Similarly, E2 treatment of cells co-transfected with RET +32.8 and pCDNA3.1 ESR1-induced luciferase activity at levels 14-fold higher than the promoter-only construct (P-value versus promoter ,0.002). Taken collectively, these data further support a model in which ESR1 is necessary and sufficient for E2-induced enhancer activity of RET 249.8 and RET +32.8.
Enhancer activity of five interacting
RET locus ESR1-binding sites does not exceed RET 249.8 and RET 132.8
in combination
Genome-wide chromatin interaction analyses in MCF-7 cells (52) identified E2-induced interactions between five ESR1-binding sites at the RET locus (RET 249.8, RET 238.1, RET 231.7, RET +4.8 and RET +32.8). Of these elements, we have already shown that only RET 249.8 and RET +32.8 display significant E2-induced regulatory activity when assayed independently (Fig. 1B) . We then set out to determine whether physical co-localization of these elements corresponded to collective regulatory activity that exceeds their independent output, constructing a luciferase vector containing all five interacting elements, or subsets of the elements (Fig. 5) . While RET 249.8 and RET +32.8 showed independent regulatory activity as before ( 12-fold versus promoter and 7-fold versus promoter E2 response, respectively), a . Finally, we hypothesized that RET 249 and RET +32 in combination might explain the majority of this increased induced response. Consistent with this idea, when assayed in combination, these sequences show 24-fold upregulation versus the promoter (versus 12-fold for RET 249.8 and 7-fold for RET +32.8). Thus, RET 249+32 displays regulatory activity that is slightly greater than additive, suggesting that the regulatory activity of the combined five ESR1-binding sites can be explained primarily by the activity of the previously identified E2 response elements.
RET 249.8 exhibits RET appropriate in vivo regulatory activity
To determine whether the identified EREs (RET 249.8 and RET 232.8) also displayed in vivo regulatory control in addition to their role in E2-responsiveness, we assayed their regulatory activity using Tol2-based stable transgenesis in zebrafish (35, 52) . While RET +32.8 did not exhibit in vivo regulatory activity at the times assayed (1 -4 days postfertilization), RET 249.8 directed broad central nervous system expression of enhanced green fluorescent protein (eGFP) (Fig. 6A) , overlapping the expression domains of endogenous ret in the central nervous system at 24 hpf (1). By 72 hpf, RET 249.8 directed discrete reporter expression in the dorsal spinal cord, consistent with the position of the ret expressing Rohon-Beard neurons and interneurons (dorsal; Fig. 6B) (1,53) ; a dense column of ventral spinal cord consistent with motor neurons (53) and in the ret-positive lateral line ganglia (1) . Consistent with its activity in neuronal populations and with the endogenous expression of ret, RET 249.8 acted as a classical enhancer in SK-N-SH human neural crest-derived neuroblastoma cells, directing luciferase expression almost 2-fold greater than the promoter-only construct (Supplementary Material, Fig. S3A ). Additionally, RET 249.8 maintains its ability respond to E2, in both SK-N-SH cells and mouse neuroblastoma Neuro2A cells, when co-transfected with an ESR1 expression vector (Supplementary Material, Fig. S3A and B) . Taken collectively, these data suggest that RET 249.8 may act as a classical enhancer that may be modulated by E2 in a tissue and stagedependent manner. 
DISCUSSION
RET is a developmentally critical gene. Its transcription has been well documented in many cell populations and is modulated by E2 and RA during development and disease (13, 14, (20) (21) (22) 24, 29, 30, 43) . We believe this is the first study to characterize specific E2 response elements at this critical locus, as well as the first breast cancer RARE. Here we have studied 10 ESR1-binding sequences and 2 RARA-binding sequences at RET, identifying one particularly potent ERE and RARE (RET 249.8) and characterizing it in detail. Additionally, we identified and characterized a second RET locus E2 response element (RET +32.8).
We demonstrate the dependence of the endogenous RET expression and both RET 249.8 and RET +32.8 regulatory activity on ESR1 for E2 modulation. We further identify multiple sequence motifs within RET 249.8 that are required for its E2-induced activity. These sites include two FOXA1-like motifs and 12 bp and 9 bp CR sequences identified by ChIP-PET and ChIP-SEQ as ESR1 CRs (12 bp CR and 9 bp CR) (30, 37) . We have also shown the dependence of RET 249.8 and RET +32.8 on TFAP2C-like motifs for E2 response. Furthermore, RET 249.8 binds both cohesin and RNA polymerase II in MCF-7 cells (54,55) consistent with other endogenous enhancers (51, 52) and supporting the idea that these sequences play regulatory roles in their genomic context. Although E2 and RA signaling display antagonistic effects on most genes they co-modulate in MCF-7 cells (29), we observe that RET transcription appears to be cooperatively controlled by these factors in these cells. Consistent with this observation, RET 249.8 is synergistically upregulated by both E2 and RA (Fig. 2) , suggesting a potentially pivotal role for RET 249.8 in integrating E2 and RA signaling. Additionally, sequence within RET 249.8 has been shown in MCF-7 cells to bind E2F1, a cell cycle regulator, and TFAP2C [Yale/UC Davis/Harvard ENCODE Group; (47, 49) ], both of which have been implicated in hormone therapy resistance in breast cancer (56) (57) (58) (59) . RET 249.8 has also been shown to bind the ESR1 co-factor SRC-3 (60,61). Additionally, the E2 responsiveness of RET 249.8 and RET +32.8 in T47D E2 responsive breast cancer cell lines suggests that these elements could be functional in multiple E2 receptor-positive breast cancers (55) . Given the established role for these pathways in breast cancer, these data may also indicate a role for RET 249.8 and RET +32.8 and the factors they interact with in breast tumor progression.
After characterizing their regulatory responses in vitro, we then establish that RET 249.8, but not RET +32.8, has the independent capacity to act as an in vivo classical tissuedependent enhancer consistent with the expression of the zebrafish RET ortholog (ret1) (1) . Whether this in vivo activity is also dependent on ESR1, RARA or another factor remains to be determined. Here we observe three classes of ESR1-binding sites; an E2-modulated tissue-specific in vivo enhancer, an in vitro ERE with no overt independent in vivo function in our transgenic assay and a three sequences that bind ESR1 
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Human Molecular Genetics, 2011, Vol. 20, No. 19 and are brought into physical proximity in response to E2 but have no overt function in either our in vitro or in vivo assays. The observation that RET 249.8 functions as both a RET ERE in MCF-7 cells and as a neuronal enhancer in vitro and in vivo suggests a potentially broader role for ERE and RARE potentially modulating classical enhancer activity. Furthermore, the final class of sequences may be postulated to recruit transcription factors or stabilize loop formation making a contribution to transcriptional control that is not overt when assayed independently. Either way, these data suggest that our expectations of what comprise biologically valuable sequences may need to be reevaluated as the range of assays to which they are subjected become progressively deeper. In the context of E2-and RA-based transcriptional control, although thousands of ESR1-and RARA-binding sites have been identified in breast cancer cell lines, their in vitro and in vivo regulatory activities remain largely untested. Our data suggest that RET 249.8 and RET +32.8 are likely to be required for E2-mediated RET transcriptional response in breast cancer. Additionally, the crosstalk between RA and E2 signaling has potential therapeutic implications for the treatment of breast cancer (29) . Consequently, regulatory elements, such as RET 249.8, which integrate RA and E2 signaling may hold further insights into breast cancer risk, progression and treatment. Similarly, understanding the disease risk and prognostic consequences of variation within these regulatory elements and the gene products that lie upstream may further refine individual patient management. We are building on this platform to determine the necessity of RET 249.8 and RET +32.8 for endogenous E2-mediated RET transcriptional modulation during development and tumor progression.
MATERIALS AND METHODS
Luciferase reporter assays
Sequences encompassing 10 ESR1-binding sites and 2 RARAbinding sites identified at the RET locus by whole genome ChIP assay on MCF-7 cells (20, (30) (31) (32) (33) were amplified and cloned (Primers and intervals; Supplementary Material, Table S2 ) into pDSMA, a Gateway-modified pGL3 (Promega) (34) . The sequences identified in each study are listed in Supplementary Material, Table S1 . The constructs were termed pDSMA_RET * , named based on their distance from the RET transcriptional start site. RET 28.7, RET +5.1 and RET +9.7 were previously termed RET HCS 28.7, RET +5.1 and RET +9.7 (34, 35) . For E2 deprivation MCF-7, T47D, MDA-MB-231, SK-N-SH or Neuro2A cells were grown for 2 days in phenol red free media supplemented with 10% charcoal-stripped fetal bovine serum, then transfected with luciferase vectors containing the binding regions or promoter-only and a renilla control using Lipofectamine 2000 (MCF-7, T47D, SK-N-SH, Neuro2A) or Lipofectamine LTX with Plus reagent (MDA-MB-231) using manufacturer's protocol. The transfected cells were treated with 10 nM 17-b-estradiol (Sigma), 1 mM all-trans RA (Sigma) or 1 mM all-trans RA and 10 nM 17-b-estradiol, or E2-deprived media with matching ethanol and then assayed using Dual-Glo Luciferase Kit (Promega).
MCF-7 siRNA luciferase experiment
E2-deprived MCF-7 cells were co-transfected with appropriate pDSMA firefly luciferase plasmid and 6 pM of appropriate Dharmacon SMARTpool siRNA for ESR1, FOXA1 or nontargeting siRNA using Lipofectamine 2000 (Invitrogen). Twenty-four hours after lipofection, the media were removed and cells were treated with ethanol or E2 as described above. Twenty-four hours after the addition of treatment, luciferase activity was performed as described above.
MDA-MB-231 transactivation
Human full-length cDNA clones from the Mammalian Gene Collection (62) for FOXA1 and ESR1 were purchased (Fisher) , subcloned into pCNDA3.1 using Infusion cloning (Stratagene, Primers, Supplementary Material, Table S3 ). pDSMA RET 249.8 or pDSMA promoter and a renilla control vector were co-transfected into MDA-MB-231 cells with pCDNA3.1 ESR1 or empty pCDNA3.1 using Lipofectamine LTX with Plus Reagent (Invitrogen). The co-transfected cells were then treated with either E2 or ethanol for 24 h. Luciferase activity was then performed using Promega Dual Glo Luciferase as described above.
Generation of mutagenized pDSMA constructs
Site-directed mutagenesis to convert motifs to EcoRV digest site was performed on motifs of interest using QuikChange w II XL Site-Directed Mutagenesis Kit (Stratagene). Primers (listed in Supplementary Material, Table S4 ) were designed using the QuikChange w Primer Design Program. Serial mutagenesis was used to create double mutants.
MCF-7 quantitative PCR
The E2-depleted cells were treated for 24 h with agonists as described in Luicferase Reporter assays and total RNA collected. cDNA was then synthesized off of total RNA. cDNA synthesized from total mRNA using random hexamers (Super Script III First Strand synthesis; Invitrogen). Quantitive polymerase chain reaction (PCR) was done using Taqman (ABI) probes for RET and 18S rRNA with Taqman Gene Expression Master Mix (ABI).
siRNA knockdown followed by quantitative PCR Reverse transfections of 30 picomoles of non-targeting siRNA (Dharmacon) or target gene-directed SMARTpool siRNA into E2 (Dharmacon) deprived MCF-7 were performed using Lipofectamine RNAimax (Invitrogen). Two days after siRNA delivery, agonist treatment was performed for 24 h as described above. Quantitative PCR was then performed as described above on total RNA extracted from siRNA treated MCF-7 cells.
Zebrafish embryo injections and analysis
Sequences studied in luciferase that have not been previously injected into AB zebrafish (Danio rerio) (35) 
(Invitrogen) cloned into the pT2GWcfosEGFP vector, a Tol2--based transgenic construct (pT2CG_RET * ) as previously described (35, 52, 63, 64) . Reporter expression directed by the sequences was then analyzed in ≥200 live G0 mosaic embryos at 24, 48, 72 and 96 h post-fertilization. If consistent expression was observed in ≥10% of embryos, the embryos were raised for G1 analysis. At 3 months of age, G0 males were crossed with AB females to identify transgene germline transmitting founders. G1 transgenic fish was screened at 24, 48, 72 and 96 h post-fertilization. Methods followed have been approved by the Johns Hopkins University Animal Care and Use Committee.
Western blot
Western blot was done on MCF-7 cell lysate collected 48 h after siRNA treatment using standard protocols. The antibodies used for the western blot were an ESR1 antibody (Santa Cruz Biotechnology), FOXA1 (AbCam) and Tubulin (Cal Biochem).
Design and generation of constructs containing multiple ESR1-binding amplicons
RET locus interacting sequences were identified from the previously published ESR1-dependent MCF-7 chromatin interaction map [(37); data set IHM001F]. Pair-wise interactions were identified between regions containing ESR1-binding sites RET 249.8 and RET 238.1, RET 249.8 and RET 231.7, RET 249.8 and RET +4.8, and RET 249.8 and RET +32.8. Vectors containing different combinations of five interacting sequences were cloned serially into the pDSMA Gateway-modified pGL3 luciferase vector using Infusion cloning (Primers; Supplementary Material, Table S5 ). During vector construction, all elements located 5 ′ of the endogenous RET promoter (RET 249.8, RET 238.1, and RET 231.7) were cloned upstream of the of the SV40 promoter, while elements 3 ′ of the endogenous RET promoter (RET +4.8 and RET +32.8) were cloned 3 ′ of the Luciferase coding sequence.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
